1.00 / AMA PRA Category 1 Credit(s)TM 1.00 / CE for Nurses
Jointly provided by Med Learning Group and Ultimate Medical Academy/Complete Conference Management
Supported by an educational grant from Teva Pharmaceuticals
This case-based enduring activity will cover the diagnosis, treatment, and management of patients with eosinophilic asthma.
This activity is designed to meet the educational needs of primary care physicians, allergists and/or immunologists, and other healthcare providers involved in the treatment of patients with eosinophilic asthma.
Upon completion of the program, participants should be able to:
Review the molecular biology describing the heterogeneous nature of asthma and associated treatment targets
Assess patients’ level of control, severity of disease, and exacerbation risk in the management of asthma
Describe the clinical trial data on emerging targeted treatment options for patients with eosinophilic asthma
Conflict Of Interest Disclosure Policy
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Monica Kraft, MD Robert and Irene Flinn Professor of Medicine Chair, Department of Medicine University of Arizona Health Sciences Center Tucson, AZ
Dr. Kraft receives research grant funding from NIH, Genentech, and Chiesi. She serves as a consultant/on the scientific advisory boards for Novartis, TEVA, Astra-Zeneca, and Genentech. She also receives royalties from Elsevier.
Michael E. Wechsler, MD, MMSc Director, Asthma Program Professor Department of Medicine Division of Pulmonary, Critical Care and Sleep Medicine National Jewish Health Denver, CO
Dr. Wechsler receives research grant funding from NIH and Novartis. He also serves as a consultant/on the scientific advisory boards for Ambit Biosciences, Astra-Zeneca, Boston Scientific, Genentech, Gliacure, Meda, Mylan, Novartis, Regeneron, Sanofi, Sunovion, Teva, Tunitas, and Vectura.
Planners, Managers, and Reviewers Disclosures
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose. Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose. Joseph Chebli, PharmD, MA, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose. Brooke Hefele, Accreditation & Outcomes Specialist for Med Learning Group, has nothing to disclose. Lisa Dorin, Senior Program Manager for Med Learning Group, has nothing to disclose.
CME Content Review The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.
CNE Content Review Barbara L. O’Brien, MSN, BSN, RN, Nurse Reviewer, has nothing to disclose.
AMA PRA Category 1 Credit(s)TM
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Med Learning Group designates this enduring activity for a maximum of 1.00 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
CE for Nurses
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.00 contact hour(s) of continuing nursing education of RNs and APNs.
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.